John G Ullman & Associates Inc. Sells 169,128 Shares of Pfizer Inc. (NYSE:PFE)

John G Ullman & Associates Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 29.3% during the 4th quarter, HoldingsChannel reports. The firm owned 407,708 shares of the biopharmaceutical company’s stock after selling 169,128 shares during the period. Pfizer comprises about 1.9% of John G Ullman & Associates Inc.’s investment portfolio, making the stock its 14th largest holding. John G Ullman & Associates Inc.’s holdings in Pfizer were worth $11,738,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of PFE. Adage Capital Partners GP L.L.C. increased its stake in shares of Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC acquired a new stake in shares of Pfizer during the fourth quarter worth about $255,000. Brookstone Capital Management boosted its holdings in Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares in the last quarter. ETF Store Inc. lifted its stake in Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. raised its holdings in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after acquiring an additional 74,487 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 2.2 %

PFE traded up $0.57 on Friday, reaching $25.96. 27,186,810 shares of the company traded hands, compared to its average volume of 42,249,816. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37. The firm has a fifty day simple moving average of $27.14 and a two-hundred day simple moving average of $28.74. The company has a market cap of $147.00 billion, a P/E ratio of 71.89, a price-to-earnings-growth ratio of 1.15 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the business posted $1.14 EPS. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PFE shares. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.